Screener
Mineralys Therapeutics, Inc. MLYS Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 5:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001933414-26-000084
| Line item | Three Months Ended / March 31, 2026 | 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $24,365 | $37,879 |
| General and administrative | 20,975 | 6,568 |
| Total operating expenses | 45,340 | 44,447 |
| Loss from operations | (45,340) | (44,447) |
| Interest income, net | 5,996 | 2,239 |
| Other income (expense) | 5 | (3) |
| Total other income, net | 6,001 | 2,236 |
Item 1. Financial Statements
FAQ
- What is Mineralys Therapeutics, Inc.'s total operating expenses?
- Mineralys Therapeutics, Inc. (MLYS) reported total operating expenses of $45.34M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s total operating expenses changed year-over-year?
- Mineralys Therapeutics, Inc.'s total operating expenses increased by 2.0% year-over-year, from $44.45M to $45.34M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s total operating expenses?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s total operating expenses has grown at a 75.7% compound annual growth rate (CAGR), from $31.48M to $170.6M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Mineralys Therapeutics, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude